1. Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment
- Author
-
Christina Reitmann, Dennis Wolford, Kenneth C. Lasseter, David E. Gutstein, Rebecca E Wrishko, William D. Hanley, Joanna Udo de Haes, K Chris Min, and Thomas Marbury
- Subjects
Male ,Cmax ,Renal function ,Kidney ,urologic and male genital diseases ,Saline flush ,Sugammadex ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,030202 anesthesiology ,Humans ,Medicine ,Pharmacology (medical) ,Renal Insufficiency ,Rocuronium ,Adverse effect ,Aged ,Pharmacology ,business.industry ,Kidney metabolism ,030208 emergency & critical care medicine ,Middle Aged ,Case-Control Studies ,Anesthesia ,Neuromuscular Blockade ,Female ,business ,Half-Life ,gamma-Cyclodextrins ,medicine.drug - Abstract
AIMS Sugammadex rapidly reverses moderate and deep rocuronium- or vecuronium-induced neuromuscular blockade at doses of 4 mg/kg and 2 mg/kg, respectively. Sugammadex is renally eliminated. This study evaluated the pharmacokinetics of sugammadex in subjects with renal impairment versus those with normal renal function. METHODS This open-label, two-part, phase 1 study included adults with moderate (creatinine clearance (CLcr) 30
- Published
- 2017
- Full Text
- View/download PDF